| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Evogene Ltd (TA: EVGN)
EVGN Technical Analysis
5
| As on 11th Jun 2023 EVGN STOCK Price closed @ 215.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 362.77 & Strong Sell for SHORT-TERM with Stoploss of 486.94 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EVGNSTOCK Price
| Open | 216.00 | Change | Price | % |
| High | 216.00 | 1 Day | -2.20 | -1.01 |
| Low | 211.20 | 1 Week | -19.70 | -8.39 |
| Close | 215.00 | 1 Month | 2.10 | 0.99 |
| Volume | 17036 | 1 Year | -420.30 | -66.16 |
| 52 Week High 635.30 | 52 Week Low 207.90 | ||||
TA Israel Most Active Stocks
| TA125 | 2008.05 | 1.06% |
| BEZQ | 472.70 | -0.06% |
| GLEX | 8.50 | 10.39% |
| CANF | 3.20 | -3.03% |
| GIVO-L | 47.30 | 0.00% |
| LUMI | 2815.00 | 1.26% |
| ELAL | 394.00 | 3.55% |
| GNRS | 78.90 | 1.41% |
| BLRX | 37.60 | -2.08% |
| TDGN-L | 171.50 | 17.55% |
TA Israel Top Gainers Stocks
TA Israel Top Losers Stocks
| EVGN Daily Charts |
EVGN Intraday Charts |
Whats New @ Bazaartrend |
EVGN Free Analysis |
|
|
EVGN Important Levels Intraday
| RESISTANCE | 224.25 |
| RESISTANCE | 221.28 |
| RESISTANCE | 219.45 |
| RESISTANCE | 217.62 |
| SUPPORT | 212.38 |
| SUPPORT | 210.55 |
| SUPPORT | 208.72 |
| SUPPORT | 205.75 |
EVGN Forecast May 2024
| 4th UP Forecast | 629.31 |
| 3rd UP Forecast | 496.44 |
| 2nd UP Forecast | 414.31 |
| 1st UP Forecast | 332.18 |
| 1st DOWN Forecast | 97.83 |
| 2nd DOWN Forecast | 15.7 |
| 3rd DOWN Forecast | -66.44 |
| 4th DOWN Forecast | -199.31 |
EVGN Weekly Forecast
| 4th UP Forecast | 340.83 |
| 3rd UP Forecast | 300.48 |
| 2nd UP Forecast | 275.53 |
| 1st UP Forecast | 250.59 |
| 1st DOWN Forecast | 179.41 |
| 2nd DOWN Forecast | 154.47 |
| 3rd DOWN Forecast | 129.52 |
| 4th DOWN Forecast | 89.17 |
EVGN Forecast2024
| 4th UP Forecast | 1016.05 |
| 3rd UP Forecast | 759.15 |
| 2nd UP Forecast | 600.35 |
| 1st UP Forecast | 441.56 |
| 1st DOWN Forecast | -11.56 |
| 2nd DOWN Forecast | -170.35 |
| 3rd DOWN Forecast | -329.15 |
| 4th DOWN Forecast | -586.05 |
Evogene Ltd ( TA Israel Symbol : EVGN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EVGN Business Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Address: 13 Gad Feinstein Street, Rehovot, Israel, 7414002
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service